141 related articles for article (PubMed ID: 7958064)
1. Induction of specific anti-tumour immunity by interferon-gamma gene-transferred murine bladder carcinoma MBT-2.
Hiura M; Hashimura T; Watanabe Y; Kuribayashi K; Yoshida O
Folia Biol (Praha); 1994; 40(1-2):49-61. PubMed ID: 7958064
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy by in vivo interferon-gamma gene transfer to murine bladder tumor].
Hashimura T; Ueda T; Hiura M; Yoshida O; Kawabata K; Watanabe Y; Takami M
Hinyokika Kiyo; 1997 Nov; 43(11):809-13. PubMed ID: 9436027
[TBL] [Abstract][Full Text] [Related]
3. [Cancer immunotherapy by murine bladder cancer cells transfected with mouse interferon-gamma gene].
Hashimura T; Hiura M; Yoshida O; Teramura Y; Kuribayashi K; Watanabe Y
Hinyokika Kiyo; 1993 Dec; 39(12):1205-8. PubMed ID: 8285171
[TBL] [Abstract][Full Text] [Related]
4. Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma.
Shiau AL; Lin CY; Tzai TS; Wu CL
Cancer Gene Ther; 2001 Jan; 8(1):73-81. PubMed ID: 11219496
[TBL] [Abstract][Full Text] [Related]
5. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1336-42. PubMed ID: 14767344
[TBL] [Abstract][Full Text] [Related]
6. [A novel experimental approach to immunotherapy against malignant brain tumor with the mouse IFN-gamma gene transfer].
Nishihara K
Nihon Geka Hokan; 1989 Jan; 58(1):18-42. PubMed ID: 2508589
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA.
Nishihara K; Miyatake S; Sakata T; Yamashita J; Kikuchi H; Kawade Y; Zu Y; Namba Y; Hanaoka M; Watanabe Y
Cancer Res; 1988 Sep; 48(17):4730-5. PubMed ID: 3136912
[TBL] [Abstract][Full Text] [Related]
8. Transfection of interferon-gamma gene in animal tumors--a model for local cytokine production and tumor immunity.
Watanabe Y
Semin Cancer Biol; 1992 Feb; 3(1):43-6. PubMed ID: 1643293
[TBL] [Abstract][Full Text] [Related]
9. Antitumor potential of interferon-gamma: retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity.
Yanagihara K; Seyama T; Watanabe Y
Nat Immun; 1994; 13(2-3):102-12. PubMed ID: 8173232
[TBL] [Abstract][Full Text] [Related]
10. Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression.
Esumi N; Hunt B; Itaya T; Frost P
Cancer Res; 1991 Feb; 51(4):1185-9. PubMed ID: 1900037
[TBL] [Abstract][Full Text] [Related]
11. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.
Gastl G; Finstad CL; Guarini A; Bosl G; Gilboa E; Bander NH; Gansbacher B
Cancer Res; 1992 Nov; 52(22):6229-36. PubMed ID: 1423266
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models.
Tüting T; Gambotto A; Baar J; Davis ID; Storkus WJ; Zavodny PJ; Narula S; Tahara H; Robbins PD; Lotze MT
Gene Ther; 1997 Oct; 4(10):1053-60. PubMed ID: 9415311
[TBL] [Abstract][Full Text] [Related]
13. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Frey AB
J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
15. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
16. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
17. Expression of major histocompatibility complex antigens in squamous cell carcinomas of the head and neck: effects of interferon gene transfer.
Arosarena OA; Baranwal S; Strome S; Wolf GT; Krauss JC; Bradford CR; Carey TE
Otolaryngol Head Neck Surg; 1999 May; 120(5):665-71. PubMed ID: 10229590
[TBL] [Abstract][Full Text] [Related]
18. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
19. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
20. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
